Omixon and TBG form Partnership for Asia Pacific
Omixon announce an Exclusive Distribution and Support Partnership for the Asia Pacific region, including China, Hong Kong, Taiwan and Australia.
Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, and TBG Biotechnology Corp. (TBG) headquartered in Taiwan announce an Exclusive Distribution and Support Partnership for the Asia Pacific region, including China, Hong Kong, Taiwan and Australia. TBG will be the exclusive distributor of Omixon’s world leading Holotype HLA product for HLA typing by NGS.
“With a common goal of driving adoption of NGS for HLA typing in the Asia Pacific markets, TBG and their extended network of distributors is the ideal partner for the Asia Pacific region to distribute Holotype HLA,” says Dr. Peter Meintjes, Chief Commercial Officer at Omixon. Additionally, “TBG’s automated liquid handling instrument, the DX-A provides a high quality, low cost solution perfectly tailored to the market dynamics of the region.”
TBG’s Director of Sales and Marketing, Willy Hsu notes that “Omixon’s Holotype HLA has emerged as the dominant global player in HLA typing by NGS, and we are delighted to have the opportunity to bring this exciting technology to our existing customers”. TBG and Omixon have successfully optimized Holotype HLA on TBG’s DX-A Automation System and are currently completing a multi-site customer validation program to ensure reproducibility and repeatability of the liquid handling automation.
With the addition of TBG, Omixon’s distributor network covers 15 countries/territories outside of the markets in which they sell Holotype HLA directly. Nora Nagy, Market Development Manager at Omixon notes that “Our distributors have played and continue to play an important part in Omixon’s ability to spread Holotype HLA to every corner of the globe. We are delighted to be working with such a highly skilled and motivated sales and technical support partner as TBG.”
TBG is an international molecular diagnostic solutions provider and has developed a dominant presence in nearly all Asia-Pacific countries within the verticals in which they provide products. “Having established our presence in most major markets in the Asia Pacific Region, our priority is the ongoing expansion of our product portfolio in diagnostics, specifically intending to acquire technologies that can disrupt on price and quality,” notes Willy Hsu.
To join the TBG Partner Network or the Omixon Distributor Network, please see the relevant contacts from this PR.
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 20 hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit http://www.omixon.com
About TBG Diagnostics
TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services
TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:
- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services
Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market – US$53 billion in 2013 and expected to reach US$74.7 billion by 2020 (This is huge to say we operate in the IVD market. More realistically, we operate in the MDx market which is growing from 10% ($6Bn USD) to 25.2% ($25Bn USD) of total IVD market share by 2024.) Targeting further growth in China – fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases.